The Cost of Getting RNA to Mumble

By Mark McQuain In my previous blog entry, I crudely summarized the genetic basis for Duchenne Muscular Dystrophy (DMD) and one pharmaceutical company’s (Sarepta) current effort to research, manufacture and finance a genetic treatment that increases the production of a muscle protein missing in patients with DMD called dystrophin. Please see my previous blog entry … Continue reading "The Cost of Getting RNA to Mumble"
Source: blog.bioethics.net - Category: Medical Ethics Authors: Tags: Health Care Allocation / Access / Public Health bioethics biotechnology Health Care Practice syndicated Source Type: blogs